IMpower010 supports adjuvant atezolizumab in early-stage NSCLC
Heather Wakelee talks through the efficacy and safety data from the IMpower010 study of postoperative atezolizumab in individuals with early-stage non-small-cell lung cancer, touching on the cost aspect and outlining the key unanswered questions (9:24).
00:00 - Efficacy data from IMpower010
03:45 - Side effects and costs
06:34 - Summary of the conclusions
07:15 - Key unanswered questions